Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Migalastat

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 72,285Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Fortrea Releases Inaugural Corporate Social Responsibility Report
    Fortrea Releases Inaugural Corporate Social Responsibility Report

    17 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/17/2964736/0/en/Fortrea-Releases-Inaugural-Corporate-Social-Responsibility-Report.html

    GLOBENEWSWIRE
    17 Oct 2024
    Share Share
    Amicus Therapeutics Announces Q2 2024 Results And Corporate Updates
    Amicus Therapeutics Announces Q2 2024 Results And Corporate Updates

    08 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/08/2926804/15991/en/Amicus-Therapeutics-Announces-Second-Quarter-2024-Financial-Results-and-Corporate-Updates.html

    GLOBENEWSWIRE
    08 Aug 2024
    Share Share
    FDA Confirms Paragraph IV Patent Litigation for Galafold (Migalastat Hydrochloride)
    FDA Confirms Paragraph IV Patent Litigation for Galafold (Migalastat Hydrochloride)

    03 Oct 2022

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-galafold-migalastat-hydrochloride-12390.pdf

    FDA
    03 Oct 2022
    Share Share
    Amicus Announces Issuance of New U.S. Composition of Matter Patent for Galafold
    Amicus Announces Issuance of New U.S. Composition of Matter Patent for Galafold

    19 Apr 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/04/19/2424256/15991/en/Amicus-Announces-Issuance-of-New-U-S-Composition-of-Matter-Patent-for-Galafold-migalastat-Strengthening-Patent-Protection-Through-2038.html

    GLOBENEWSWIRE
    19 Apr 2022
    Share Share
    Amicus spins off gene therapy unit in $600M SPAC deal
    Amicus spins off gene therapy unit in $600M SPAC deal

    30 Sep 2021

    // Ben Adams FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/amicus-spins-off-gene-therapy-unit-600m-spac-deal-as-ceo-moves-over-to-caritas-therapeutics

    Ben Adams FIERCEBIOTECH
    30 Sep 2021
    Share Share
    Chiesi’s flagship Fabry drug heads for FDA verdict in early 2021
    Chiesi’s flagship Fabry drug heads for FDA verdict in early 2021

    13 Aug 2020

    // Phil Taylor PHARMAPHORUM

    https://pharmaphorum.com/news/chiesis-flagship-fabry-drug-heads-for-fda-verdict-in-early-2021/

    Phil Taylor PHARMAPHORUM
    13 Aug 2020
    Share Share